STAT1 and non-small cell lung carcinoma: Previously, we identified an AKR1C1 enzymatic-independent mechanism that induced STAT1 and STAT3 activation in treatment-naïve NSCLC cells [24] and demonstrated that this activation could be attenuated by ruxolitinib.